2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable valuations. A stock price can tell you a lot, but it doesn't tell you everything.
Before committing your cash, it's important to look beyond recent share performance and at the underlying business you want to buy. With that in mind, here are two remarkable healthcare companies to consider now.
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading up by about 42% over the trailing 12 months. The company is riding on the wave of multiple business successes, the most recent being the earliest slate of approvals for the first-ever gene-editing therapy to garner the regulatory green light. The therapy, called by its brand name of Casgevy (also known as exa-cel), was developed in partnership with CRISPR Therapeutics.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 440 €, das unter 452.85 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -2.84%.
